ENTITY
China Biologic Products

China Biologic Products (CBPO US)

28
Analysis
Health Care • United States
China Biologic Products Holdings, Inc. operates as a biopharmaceutical company. The Company researches, develops, and produces human plasma-based pharmaceutical and coagulation factor products in the form of tablets, injections, capsules, and syrups. China Biologic Products also distributes pharmaceutical products. China Biologic Products serves clients in China.
more
•07 Nov 2019 14:59

CITIC Envirotech's Privatisation Offer

Back on the 12 November 2014, CITIC Environment and KKR China Water jointly announced a pre-conditional Offer for  United Envirotech Ltd (as Citic...

Logo
784 Views
Share
•24 Sep 2019 04:33

Last Week in GER Research: Topsports, Bitauto, Cloudminds, Manulife, Maple Ind. Trust and Budweiser

Below is a recap of the key IPO and event-driven research produced by the Global Equity Research team. This week, we assess the IPO prospects for...

Logo
880 Views
Share
•20 Sep 2019 03:06

China Biologic's Privatisation Redux

On Wednesday after market close, China Biologic Products (CBPO US) announced a surprising privatisation bid from a consortium for $120 per ADS. The...

Logo
932 Views
Share
•19 Sep 2019 13:01

Vital Fluids: Proposal Rejuvenates China Biologics

On the 19 June last year, CITIC Capital Holdings made an unsolicited, preliminary non-binding proposal for China Biologic Products (CBPO US) - a...

Logo
764 Views
Share
•19 Mar 2019 03:30

China Blood Products: Deals Highlight Values

Grifols SA (GRF SM) and Shanghai RAAS Blood Products Co Ltd (002252.SZ) recently announced an asset exchange that effectively combines the...

Share
x